The effect of DSP-2230/placebo on renal functio

Phase 1

Completed

• Conditions: Peripheral Neuropathic Pain; Nervous System Diseases

• Registration Number: ISRCTN02543559
• Lead Sponsor: Sunovion Pharmaceuticals Europe Ltd (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-11-12
• Study Completion: 2013-12-01
• Last Update Posted: 25 November 2019

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 44

Inclusion Criteria

1. All subjects (males) will be in good health aged = 18 and = 55 years with no evidence of systemic disease
2. Be able to comply with all aspects of the protocol
3. Able to give written informed consent to participate in the study

Exclusion Criteria

1. All subjects will not have, or have had a history of, clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, haematological or other major disorders
2. They will not have, or have had a history of, drug or alcohol abuse
3. Will not have participated in a clinical study with an investigational medicinal product (IMP) within 3 months of randomisation into the current study
4. Will not have donated or lost >500 mL of blood or blood products in the 3 months preceding the start of dosing

Study & Design

• Study Type: Interventional
• Study Design: Not specified